U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula CO3.Al.Na.2HO
Molecular Weight 143.9949
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIHYDROXYALUMINUM SODIUM CARBONATE

SMILES

[OH-].[OH-].[Na+].[Al+3].[O-]C([O-])=O

InChI

InChIKey=SEIGJEJVIMIXIU-UHFFFAOYSA-J
InChI=1S/CH2O3.Al.Na.2H2O/c2-1(3)4;;;;/h(H2,2,3,4);;;2*1H2/q;+3;+1;;/p-4

HIDE SMILES / InChI
Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula CO3
Molecular Weight 60.0089
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Al
Molecular Weight 26.9815
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Potash (Dihydroxyaluminum Sodium Carbonate), a component of Kompensan-S Forte in Germany, is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. Kompensan-S Forte is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins.

Originator

Pfizer
420
Curator's Comment: # Pfizer

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Kompensan

Approved Use

Gastrointestinal disorders: Dyspepsia, Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Hyperphosphatemia
PubMed

PubMed

TitleDatePubMed
Studies on antacids. V. The preparation and properties of dihydroxy aluminum sodium carbonate.
1955 Apr
Exchange of sodium by magnesium in aluminum hydroxycarbonate gel.
1984 Jul
Studies of neutralizing properties of antacid preparations. Part 4: Application of Weibull distribution function to neutralization of dihydroxyaluminum sodium carbonate.
1988 Jul
Automation of dihydroxyaluminum sodium carbonate analysis in antacid tablets by energy dispersive X-ray fluorescence.
1990 May-Jun
Effect of pepsin on the kinetics of HCl neutralization by dihydroxyaluminum sodium carbonate, hydrotalcite and dihydroxyaluminum aminoacetate.
1991
Patents

Patents

03994954
9
04584077
8
05739318
8
06555570
9
08404650
8
20120045381
8
US2783124
8
US4438085
8

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Dyspepsia: 500 to 600 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Duodenal Ulcer: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Erosive Esophagitis: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Gastric Ulcer: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Gastroesophageal Reflux Disease: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Zollinger-Ellison Syndrome: 500 to 3600 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Hyperphosphatemia: 500 to 1000 mg orally 4 times a day, with meals and at bedtime. The dosage should be titrated to the serum phosphate level.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:02:44 UTC 2023
Edited
by admin
on Fri Dec 15 15:02:44 UTC 2023
Record UNII
84H8Z9550J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIHYDROXYALUMINUM SODIUM CARBONATE
II   MART.   MI   USP   VANDF   WHO-DD  
Systematic Name English
SODIUM (T-4)-(CARBONATO(2-)-O,O')DIHYDROXYALUMINATE(1-)
Common Name English
ALUMINUM, (CARBONATO(1-)-O)DIHYDROXY-, MONOSODIUM SALT
Common Name English
Dihydroxyaluminum sodium carbonate [WHO-DD]
Common Name English
DIHYDROXYALUMINUM SODIUM CARBONATE [USP MONOGRAPH]
Common Name English
ALUMINATE(1-), (CARBONATO(2-)-.KAPPA.O,.KAPPA.O')DIHYDROXY-, SODIUM (1:1), (T-4)-
Systematic Name English
ALUMINATE(1-), (CARBONATO)DIHYDROXY-, SODIUM
Common Name English
SODIUM (CARBONATO)DIHYDROXYALUMINATE(1-)
Common Name English
DASC
Common Name English
ALUMINATE(1-), (CARBONATO(2-)-.KAPPA.O)DIHYDROXY-, SODIUM
Common Name English
DIHYDROXYALUMINUM SODIUM CARBONATE [II]
Common Name English
DIHYDROXYALUMINUM SODIUM CARBONATE [MART.]
Common Name English
DIHYDROXYALUMINUM SODIUM CARBONATE [MI]
Common Name English
ROLAIDS (PRE-1995)
Brand Name English
CARBALDRATE ANHYDROUS
Common Name English
ALUMINIUM, (CARBONATO(1-)-O)DIHYDROXY-, MONOSODIUM SALT
Common Name English
DIHYDROXYALUMINIUM SODIUM CARBONATE
Systematic Name English
DIHYDROXYALUMINUM SODIUM CARBONATE [VANDF]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 331.11
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
NCI_THESAURUS C29701
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
CFR 21 CFR 331.15
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
Code System Code Type Description
RXCUI
23163
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
PRIMARY RxNorm
NCI_THESAURUS
C76484
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
PRIMARY
ECHA (EC/EINECS)
240-536-4
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
PRIMARY
MESH
C016386
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
PRIMARY
CAS
539-68-4
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
SUPERSEDED
SMS_ID
100000079203
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
PRIMARY
DAILYMED
84H8Z9550J
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
PRIMARY
MERCK INDEX
m4472
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
PRIMARY Merck Index
EVMPD
SUB13596MIG
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
PRIMARY
EPA CompTox
DTXSID101340737
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
PRIMARY
CAS
12011-77-7
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
ALTERNATIVE
FDA UNII
84H8Z9550J
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
PRIMARY
CAS
16482-55-6
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
PRIMARY
PUBCHEM
9793815
Created by admin on Fri Dec 15 15:02:44 UTC 2023 , Edited by admin on Fri Dec 15 15:02:44 UTC 2023
PRIMARY
Related Record Type Details
Structure of CARBALDRATE
SOLVATE->ANHYDROUS
Related Record Type Details
Structure of CARBONATE ION
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966